Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vismodegib in Resectable Pancreatic Ductal Adenocarcinoma
NCT01096732Phase 2Terminated
- Start
- Feb 2011
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vismodegib in pancreatic ductal adenocarcinoma (PDAC). Started Feb 2011; status: terminated.
02
Drugs
vismodegib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01096732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01096732.